Alimera Sciences’ (ALIM) Neutral Rating Reaffirmed at Alliance Global Partners

Alliance Global Partners reaffirmed their neutral rating on shares of Alimera Sciences (NASDAQ:ALIMFree Report) in a research note published on Tuesday, Benzinga reports.

Several other brokerages have also recently commented on ALIM. Maxim Group reissued a hold rating on shares of Alimera Sciences in a research report on Tuesday. HC Wainwright cut Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price target for the company. in a research report on Tuesday. Finally, cut Alimera Sciences from a buy rating to a hold rating in a research report on Tuesday, April 30th.

Check Out Our Latest Stock Analysis on Alimera Sciences

Alimera Sciences Stock Down 0.4 %

ALIM stock opened at $5.52 on Tuesday. The business has a 50-day moving average of $3.36 and a 200-day moving average of $3.65. Alimera Sciences has a fifty-two week low of $2.60 and a fifty-two week high of $5.65. The company has a debt-to-equity ratio of 1.71, a current ratio of 2.62 and a quick ratio of 2.51. The stock has a market capitalization of $289.19 million, a P/E ratio of -3.52 and a beta of 1.15.

Alimera Sciences (NASDAQ:ALIMGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08). Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. The company had revenue of $23.01 million for the quarter, compared to analyst estimates of $23.72 million. During the same period last year, the company posted ($0.71) earnings per share. On average, sell-side analysts anticipate that Alimera Sciences will post -0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alimera Sciences

Hedge funds have recently added to or reduced their stakes in the stock. Fifth Lane Capital LP bought a new position in Alimera Sciences during the 1st quarter worth $83,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Alimera Sciences in the 1st quarter valued at $169,000. Ancora Advisors LLC acquired a new stake in shares of Alimera Sciences in the 1st quarter valued at $915,000. Worth Venture Partners LLC acquired a new stake in shares of Alimera Sciences in the 3rd quarter valued at $1,840,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after purchasing an additional 396,506 shares in the last quarter. Institutional investors own 99.83% of the company’s stock.

Alimera Sciences Company Profile

(Get Free Report)

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

Featured Stories

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.